Head and Neck Cancer Clinical Trial
Official title:
Phase II Study of Cetuximab Anti-Epidermal Growth Factor Receptor (EGFr) Antibody in Combination With Chemotherapy in Patients With Metastatic or Recurrent Squamous Cell Head and Neck Carcinoma
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill
them or deliver tumor-killing substances to them without harming normal cells. Drugs used in
chemotherapy use different ways to stop tumor cells from dividing so they stop growing or
die. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of cetuximab plus cisplatin in treating
patients who have metastatic or recurrent cancer of the head and neck that has not responded
to previous cisplatin-based chemotherapy.
OBJECTIVES: I. Determine the response rate, duration of response, and survival in patients
with metastatic or recurrent squamous cell carcinoma of the head and neck treated with
cetuximab and cisplatin after failure of an initial cisplatin-based chemotherapy regimen.
II. Determine the efficacy, safety, and toxicity of this regimen in these patients. III.
Assess the quality of life of patients treated with this regimen.
OUTLINE: This is a multicenter study. Part I (courses 1 and 2): Patients are assigned to 1
of 2 treatment groups based on prior cisplatin-based chemotherapy regimen: Group 1 (prior
cisplatin with paclitaxel): Patients receive cisplatin IV over 1 hour on day 1 and
fluorouracil IV continuously on days 1-4. Group 2 (prior cisplatin with fluorouracil):
Patients receive cisplatin IV over 1 hour and paclitaxel IV over 3 hours on day 1. Both
groups: Treatment repeats every 3 weeks for 2 courses. Patients who achieve partial or
complete response after completion of course 2 are taken off study. Patients with stable
disease or disease progression after completion of course 2 proceed to part II of the study.
Part II (courses 3-6): Patients are stratified by response to initial cisplatin-based
chemotherapy regimen (stable disease vs disease progression). Patients receive a test dose
of cetuximab IV over 10 minutes on day 1. Patients who do not experience grade 4
anaphylactic reaction receive a loading dose of cetuximab IV over 2 hours beginning 30
minutes after completion of test dose. Patients receive cisplatin IV over 1 hour beginning 1
hour after completion of cetuximab infusion on day 1. Patients receive maintenance cetuximab
IV over 1 hour on day 8. Maintenance cetuximab repeats weekly. Combination treatment repeats
every 3 weeks for a maximum of 4 courses. Patients with stable or responding disease after
completion of course 6 may continue to receive cetuximab alone in the absence of disease
progression and at the discretion of the protocol investigator and sponsor. Quality of life
is assessed before course 1, at the completion of courses 2, 4, and 6, and then at 4 weeks
after completion of study. Patients are followed at 4 weeks.
PROJECTED ACCRUAL: Approximately 175 patients will be accrued for this study within 8
months.
;
Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |